Pelthos Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Mar 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 19, 2026
PTHS$8.90-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity (Deficit
FOR THE YEAR ENDED DECEMBER 31, 2025
| Preferred AShares | PreferredA SharesPar | PreferredC Shares | PreferredC SharesPar | CommonShares | Par | AdditionalPaid-inCapital | AccumulatedDeficit | TotalStockholders’Equity (Deficit) |
| Balance, December 31, 2024 | — | $— | 2,600 | $— | 610,389 | $— | $18,761 | $(21,475) | $(2,714) |
|---|---|---|---|---|---|---|---|---|---|
| Stock-based compensation | — | — | — | — | — | — | 3,954 | — | 3,954 |
| Restricted stock unit expense | — | — | — | — | 47,080 | — | 1,507 | — | 1,507 |
| Shares issued for services | — | — | — | — | 3,081 | — | 53 | — | 53 |
| Shares issued for cash | — | — | — | — | 1,650 | — | — | — | — |
| Shares issued for conversion of notes | — | — | — | — | 48,938 | — | 737 | — | 737 |
| Exercise of stock options | — | — | — | — | 19,538 | — | 206 | — | 206 |
| Stock split | — | — | — | — | 7,747 | — | — | — | — |
| Shares issued in Acquisition of LNHC, Inc. | 31,278 | — | — | — | — | — | 39,410 | — | 39,410 |
| Shares issued in PIPE Financing | 50,100 | — | — | — | — | — | 38,678 | — | 38,678 |
| Conversion of Preferred A Shares | (24,960) | — | — | — | 2,496,000 | — | — | — | — |
| Royalty obligation extinguishment | — | — | — | — | — | — | 369 | — | 369 |
| Net loss | — | — | — | — | — | — | — | (43,319) | (43,319) |
| Balance, December 31, 2025 | 56,418 | $— | 2,600 | $— | 3,234,423 | $— | $103,675 | $(64,794) | $38,881 |
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)
FOR THE YEAR ENDED DECEMBER 31, 2024
| Preferred AShares | PreferredA SharesPar | PreferredC Shares | PreferredC SharesPar | CommonShares | Par | AdditionalPaid-inCapital | AccumulatedDeficit | TotalStockholders’Equity (Deficit) |
| Balance, December 31, 2023 | 600,000 | $— | — | $— | 390,634 | $— | $7,075 | $(13,520) | $(6,445) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based compensation | — | — | — | — | — | — | 1,455 | — | 1,455 | |||
| Restricted stock unit expense | — | — | — | — | 6,450 | — | 105 | — | 105 | |||
| Shares issued for services | — | — | — | — | 19,287 | — | 239 | — | 239 | |||
| Shares issued for cash | — | — | — | — | 110,000 | — | 5,972 | — | 5,972 | |||
| Shares issued for conversion of notes | — | — | — | — | 25,350 | — | 1,363 | — | 1,363 | |||
| Issuance cost from common stock issued for extension of bridge loan | — | — | — | — | 8,112 | — | 448 | — | 448 | |||
| Standby agreement | — | — | — | — | 3,750 | — | — | — | — | |||
| Recission of common stock | — | — | — | — | (11,113) | — | (92) | — | (92) | |||
| Transfer of liabilities to Chromocell Corp. for preferred C shares | — | — | 2,600 | — | — | — | 2,153 | — | 2,153 | |||
| Shares issued for payment of accounts payable | — | — | — | — | 1,000 | — | 7 | — | 7 | |||
| Stock repurchase | — | — | — | — | (8,620) | — | (74) | — | (74) | |||
| Conversion of Preferred A Shares | (600,000) | — | — | — | 49,943 | — | — | — | — | |||
| Shares issued for cash under equity line of credit, net of issuance costs and for paydown on notes payable and accrued interest | — | — | — | — | 15,596 | — | 110 | — | 110 | |||
| Net loss | — | — | — | — | — | — | — | (7,955) | (7,955) | |||
| Balance, December 31, 2024 | — | $— | 2,600 | $— | 610,389 | $— | $18,761 | $(21,475) | $(2,714) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.